Low glycemic index potato biscuits alleviate physio-histological damage and gut dysbiosis in rats with type-2 diabetes mellitus induced by high-sugar and high-fat diet and streptozotocin

Total dietary fiber of tartary buckwheat alleviates T2DM through the IRS-1/PI3K/AKT pathway and gut microbiota-bile acids-TGR5/FXR axis in db/db mice

Buckwheat dietary fiber has good hypoglycemic activity, with its water-soluble parts and modification widely studied, however, the specific effects and mechanisms of action regarding buckwheat total dietary fiber (BDF) to improve T2DM need to be further explored. In this study, we investigated the improvement of diabetes-related symptoms in db/db mice by 10 % BDF and explored the possible mechanisms. The results showed that hyperglycemia, hyperlipemia, insulin resistance, elevated body weight, severe inflammatory response and impaired intestinal function were significantly improved after 8 weeks of BDF intervention. Moreover, BDF was able to ameliorate the distribution of gut microbiota, enhance the bacteria associated with T2DM, and improve glucose metabolism by altering the levels of the metabolites of gut microbiota, bile acids (BAs), and their receptors, TGR5 and FXR. In addition, BDF activated the hepatic IRS-1/PI3K/AKT pathway which can reduce hepatic gluconeogenesis and promoted glycogen synthesis. Taken together, our results suggest that BDF can alleviate T2DM symptoms by activating the IRS-1/PI3K/AKT pathway and the gut microbiota-BAs-TGR5/FXR axis. The results of this study deepen the exploration of the active ingredients of cereals and suggesting a scientific basis for the development of glucose-lowering functional foods and nutraceuticals.

The effectiveness of a community-based online low-glycaemic index diet and lifestyle recommendations intervention for people with type 2 diabetes: a randomized controlled trial

BACKGROUND

The community health workers (CHWs)-led model is an important strategy for managing type 2 diabetes mellitus (T2DM) in China. However, existing community-based dietary and health education interventions in diabetes management are insufficient. Meanwhile, emerging mobile health (mHealth) has emerged as a promising tool for improving disease management. Current evidence on the combined efficacy of mHealth technologies and CHWs strategies remains limited.

OBJECTIVE

This study evaluates the effectiveness of an online dietary and health education intervention delivered through a tertiary hospital's WeChat official account (WOA) for T2DM patients, examining its influence on glycated hemoglobin (HbA1c) levels, body mass index (BMI), serum lipid profiles, and diabetes-specific quality of life (DSQL).

METHODS

This randomized clinical trial was conducted in two community health centers in China, enrolling adults diagnosed with T2DM. Participants were randomly assigned to two groups over 3 months. The control group received standard care, while the intervention group accessed online low glycaemic index (GI) dietary and lifestyle recommendations via the WOA. This group was instructed to monitor blood glucose levels, upload daily dietary photos, review health education notifications, and participate in real-time communication with the diabetes management team via the WOA.

RESULTS

A total of 178 participants were randomized to the control group (mean [SD] age, 57.07 [10.96] years, n = 89) and the intervention group (mean [SD] age, 57.18 [10.61] years, n = 89). After 3 months, significant improvements were observed in the intervention group compared to the control group, with lower HbA1c levels (mean 7.82%, SD 0.43%; p = 0.001), BMI (mean 24.35, SD 1.25 kg/m2; p < 0.001), low-density lipoprotein cholesterol (mean 2.38, SD 0.21 mmol/L; p < 0.001), and DSQL scores (mean 43.24, SD 7.23; P < 0.001), whereas high-density lipoprotein cholesterol (mean 1.35, SD 0.37 mmol/L; p = 0.001) was significantly higher. Subgroup analysis at 3 months showed that age, education, disease duration, comorbidity, and BMI influenced the effectiveness of HbA1c reduction.

CONCLUSION

Overall, the WOA-based intervention effectively engages patients in community diabetes management, leading to improved glycemic control, weight reduction, lipid metabolism optimization, and better quality of life.

TRIAL REGISTRATION

ChiCTR2400081045.

Potassium sodium hydrogen citrate intervention on gut microbiota and clinical features in uric acid stone patients

The high recurrence rate of renal uric acid stone (UAS) poses a significant challenge for urologists, and potassium sodium hydrogen citrate (PSHC) has been proven to be an effective oral dissolution drug. However, no studies have investigated the impact of PSHC on gut microbiota and its metabolites during stone dissolution therapy. We prospectively recruited 37 UAS patients and 40 healthy subjects, of which 12 patients completed a 3-month pharmacological intervention. Fasting vein blood was extracted and mid-stream urine was retained for biochemical testing. Fecal samples were collected for 16S ribosomal RNA (rRNA) gene sequencing and short chain fatty acids (SCFAs) content determination. UAS patients exhibited comorbidities such as obesity, hypertension, gout, and dyslipidemia. The richness and diversity of the gut microbiota were significantly decreased in UAS patients, Bacteroides and Fusobacterium were dominant genera while Subdoligranulum and Bifidobacterium were poorly enriched. After PSHC intervention, there was a significant reduction in stone size accompanied by decreased serum uric acid and increased urinary pH levels. The abundance of pathogenic bacterium Fusobacterium was significantly downregulated following the intervention, whereas there was an upregulation observed in SCFA-producing bacteria Lachnoclostridium and Parasutterella, leading to a significant elevation in butyric acid content. Functions related to fatty acid synthesis and amino acid metabolism within the microbiota showed upregulation following PSHC intervention. The correlation analysis revealed a positive association between stone pathogenic bacteria abundance and clinical factors for stone formation, while a negative correlation with SCFAs contents. Our preliminary study revealed that alterations in gut microbiota and metabolites were the crucial physiological adaptation to PSHC intervention. Targeted regulation of microbiota and SCFA holds promise for enhancing drug therapy efficacy and preventing stone recurrence. KEY POINTS: • Bacteroides and Fusobacterium were identified as dominant genera for UAS patients • After PSHC intervention, Fusobacterium decreased and butyric acid content increased • The microbiota increased capacity for fatty acid synthesis after PSHC intervention.

Changes in the Composition and Diversity of the Intestinal Microbiota Associated with Carbohydrate Consumption in Type 2 Diabetes Mellitus Patients

Type 2 diabetes mellitus (T2DM) is a multifactorial disease, influenced by dietary and environmental factors that can modify the intestinal microbiota. The aim of this study was to evaluate changes in the composition and diversity of the intestinal microbiota associated with carbohydrate (CHO) consumption in T2DM patients. Forty patients participated, with and without T2DM. Fecal samples were collected for the characterization of microbial diversity from the massive sequencing of the 16S rRNA gene. Carbohydrate consumption was quantified using the Frequency Consumption Foods questionnaire (FCF), the groups were categorized according to Body Mass Index (BMI) and BMI + CHO consumption. The group without T2DM showed normal biochemical and anthropometric parameters, although they had a high carbohydrate consumption compared to the group with T2DM. At the phylum level, there were differences in relative abundance; the control overweight group (CL-OW > CHO) and T2DM-Normal Weight > CHO patients had increased Bacteroides and decreased Firmicutes. In contrast, the CL-OW > CHO and T2DM-OW < CHO patients, showed reduced Bacteroidetes and an elevated amount of Firmicutes. At the genus level, the differences were in the relative abundance of Roseburia, Clostridium_IV, Prevotella, and Sporobacter, associated with the consumption of carbohydrates. The groups that consumed high amounts of carbohydrates, regardless of whether they had diabetes mellitus or were overweight, had a significantly reduced proportion of Faecalibacterium, an altered proportion of Bacteroides. The high consumption of carbohydrates showed considerable modifications in the composition and diversity of the bacterial communities.

The Effect of Bifidobacterium animalis subsp. lactis MN-Gup on Glucose Metabolism, Gut Microbiota, and Their Metabolites in Type 2 Diabetic Mice

Probiotics have garnered increasing attention as a potential therapeutic approach for type 2 diabetes mellitus (T2DM). Previous studies have confirmed that Bifidobacterium animalis subsp. lactis MN-Gup (MN-Gup) could stimulate the secretion of glucagon-like peptide-1 (GLP-1) in NCI-H716 cells, but whether MN-Gup has a hypoglycemic effect on T2DM in vivo remains unclear. In this study, a T2DM mouse model was constructed, with a high-fat diet and streptozotocin in mice, to investigate the effect of MN-Gup on diabetes. Then, different doses of MN-Gup (2 × 109 CFU/kg, 1 × 1010 CFU/kg) were gavaged for 6 weeks to investigate the effect of MN-Gup on glucose metabolism and its potential mechanisms. The results showed that a high-dose of MN-Gup significantly reduced the fasting blood glucose (FBG) levels and homeostasis model assessment-insulin resistance (HOMA-IR) of T2DM mice compared to the other groups. In addition, there were significant increases in the short-chain fatty acids (SCFAs), especially acetate, and GLP-1 levels in the MN-Gup group. MN-Gup increased the relative abundance of Bifidobacterium and decreased the number of Escherichia-Shigella and Staphylococcus. Moreover, the correlation analysis revealed that Bifidobacterium demonstrated a significant positive correlation with GLP-1 and a negative correlation with the incremental AUC. In summary, this study demonstrates that Bifidobacterium animalis subsp. lactis MN-Gup has significant hypoglycemic effects in T2DM mice and can modulate the gut microbiota, promoting the secretion of SCFAs and GLP-1.

A Metabolite Perspective on the Involvement of the Gut Microbiota in Type 2 Diabetes

Type 2 diabetes (T2D) is a commonly diagnosed condition that has been extensively studied. The composition and activity of gut microbes, as well as the metabolites they produce (such as short-chain fatty acids, lipopolysaccharides, trimethylamine N-oxide, and bile acids) can significantly impact diabetes development. Treatment options, including medication, can enhance the gut microbiome and its metabolites, and even reverse intestinal epithelial dysfunction. Both animal and human studies have demonstrated the role of microbiota metabolites in influencing diabetes, as well as their complex chemical interactions with signaling molecules. This article focuses on the importance of microbiota metabolites in type 2 diabetes and provides an overview of various pharmacological and dietary components that can serve as therapeutic tools for reducing the risk of developing diabetes. A deeper understanding of the link between gut microbial metabolites and T2D will enhance our knowledge of the disease and may offer new treatment approaches. Although many animal studies have investigated the palliative and attenuating effects of gut microbial metabolites on T2D, few have established a complete cure. Therefore, conducting more systematic studies in the future is necessary.